Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210
Open Access
- 1 January 2019
- journal article
- research article
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 16 (1) , 173-+
Abstract
Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210Keywords
This publication has 23 references indexed in Scilit:
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease ProgressionJAMA Dermatology, 2015
- Toxicities of Immunotherapy for the PractitionerJournal of Clinical Oncology, 2015
- Immune Checkpoint Blockade in Cancer TherapyJournal of Clinical Oncology, 2015
- Signaling pathways in the development of infantile hemangiomaJournal of Hematology & Oncology, 2014
- Update on the classification of hemangiomaJournal of Oral and Maxillofacial Pathology, 2014
- Haemangioma: clinical course, complications and managementBritish Journal of Dermatology, 2013
- Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0Journal of the American Academy of Dermatology, 2012
- Eruptive pyogenic granulomas developing after drug hypersensitivity reactionJournal of the American Academy of Dermatology, 2009
- Growth Characteristics of Infantile Hemangiomas: Implications for ManagementPediatrics, 2008
- Pyogenic granuloma with multiple and satellite involvement after a burn in a 5-year-old childThe Journal of Dermatology, 2006